Research project on leukaemia in children : A new, twofold approach
en-GBde-DEes-ESfr-FR

Research project on leukaemia in children : A new, twofold approach


Scientists at the University of Duisburg-Essen are researching new therapies for aggressive forms of childhood leukaemia. For the first time, their approach tries to distinguish between two subtypes using so-called nanobody PROTACs. These attack diseased tissue while sparing healthy cells. The José Carreras Leukaemia Foundation is supporting the project, led by Prof. Dr. Shirley Knauer and Dr. Mike Blueggel from the Faculty of Biology, with 143,740 euros for two years.

The research focuses on molecules that break down certain proteins in cancer cells: nanobody PROTACs (proteolysis targeting chimeras). They couple a binding molecule for the target protein with a signal that causes the cell to destroy this particular protein. This allows a disease-relevant protein to be removed in a targeted manner without damaging healthy structures.

The target protein in this case is the enzyme Taspase 1, which plays a central role in particularly aggressive forms of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). So far, it has been difficult to develop effective strategies against this enzyme. Therefore, researchers are now exploiting differences in the internal degradation machinery of cancer cells for the first time: they want to develop PROTACs that specifically degrade Taspase 1 in the respective form of leukaemia.

Another innovation is the use of so-called helicons – small spiral-shaped proteins that, as part of biological PROTACs, establish a connection with the degradation factors described above. This enables the targeted destruction of the protein of interest.

‘With this dual novel approach, we are opening up an entirely new avenue for personalised leukaemia treatment,’ explains Dr. Mike Blueggel. ‘This project could be groundbreaking, not only for research, but also for the long-term treatment of these particularly aggressive diseases.’

Image: Artistic representation of some of the structures described: A white leukaemia cell floats in the bloodstream surrounded by red blood cells. The shiny metallic helix structure next to it represents the Helicon. © UDE / Shirley Knauer, generated with AI

Fichiers joints
  • Artistic representation of some of the structures described: A white leukaemia cell floats in the bloodstream surrounded by red blood cells. The shiny metallic helix structure next to it represents the Helicon. © UDE / Shirley Knauer, generated with AI.
Regions: Europe, Germany, United Kingdom
Keywords: Science, Life Sciences, Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Témoignages

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Nous travaillons en étroite collaboration avec...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement